Imiquimod dihydrochloride
Based on 52 publication(s) in Google Scholar
Imiquimod (R 837) dihydrochloride, an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 2995277-02-4
- 分子式: C14H18Cl2N4
- 分子量:313.23
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
MedChemExpress（MCE）の使用を引用している文献 Imiquimod dihydrochloride
More- Nature. 2025 May;641(8061):202-210. [Abstract]
- Nat Commun. 2016 May 25:7:11724. [Abstract]
- J Nanobiotechnology. 2022 May 14;20(1):228. [Abstract]
- Nucleic Acids Res. 2021 Jan 8;49(D1):D1113-D1121. [Abstract]
- Theranostics. 2023 Apr 9;13(7):2226-2240. [Abstract]
- Acta Pharm Sin B. 2026 Jul 15.
- Acta Pharm Sin B. 2024 Oct;14(10):4360-4377. [Abstract]
- Adv Sci (Weinh). 2024 Sep;11(35):e2405158. [Abstract]
- MedComm (2020). 2022 Mar 4;3(1):e120. [Abstract]
- Biomaterials. 2022 Mar:282:121411. [Abstract]
- Biomaterials. 2021 Apr:271:120724. [Abstract]
- Mol Biomed. 2025 Nov 13;6(1):108. [Abstract]
- J Control Release. 2023 Sep:361:443-454. [Abstract]
- Cell Death Dis. 2025 Jan 20;16(1):31. [Abstract]
- J Immunother Cancer. 2026 Jun 3;14(6):e014392.
- Cell Commun Signal. 2024 Nov 25;22(1):565. [Abstract]
- Cell Commun Signal. 2023 Aug 18;21(1):215. [Abstract]
- Drug Deliv. 2023 Dec;30(1):2183814. [Abstract]
- Biodes Manuf. 2025 May 22.
- Cell Rep. 2021 Feb 2;34(5):108724. [Abstract]
- J Invest Dermatol. 2022 May;142(5):1349-1359.e8. [Abstract]
- Pharmaceutics. 2025 Nov 20;17(11):1503. [Abstract]
- J Ethnopharmacol. 2026 Oct 28:369:121903. [Abstract]
- J Ethnopharmacol. 2024 Apr 6:323:117711. [Abstract]
- J Agric Food Chem. 2024 Jan 17;72(2):1055-1066. [Abstract]
- Inflamm Res. 2026 Apr 17;75(1):93. [Abstract]
- EMBO Rep. 2022 Feb 3;23(2):e53499. [Abstract]
- Int Immunopharmacol. 2024 Sep 21;142(Pt B):113190. [Abstract]
- ACS Appl Bio Mater. 2019 Feb 18;2(2):874-883. [Abstract]
- J Periodontal Res. 2025 Feb 25. [Abstract]
- Am J Respir Cell Mol Biol. 2023 Mar;68(3):256-266. [Abstract]
- Diam Relat Mater. 2023 May 26, 110058.
- Eur J Pharm Sci. 2026 Mar 19:107510. [Abstract]
- Sci Rep. 2024 Mar 4;14(1):5237. [Abstract]
- J Cell Mol Med. 2024 Apr;28(8):e18356. [Abstract]
- J Inflamm Res. 2025 Mar 20:18:4213-4231. [Abstract]
- FASEB J. 2025 Dec 15;39(23):e71278. [Abstract]
- Arch Microbiol. 2025 Oct 6;207(11):290. [Abstract]
- FEBS Lett. 2021 Oct;595(19):2447-2462. [Abstract]
- Tuberculosis. 2025 Oct 14:155:102698. [Abstract]
- Biochem Biophys Res Commun. 2024 Apr 16:704:149661. [Abstract]
- Ir J Med Sci. 2025 Dec 13. [Abstract]
- SSRN. 2025 Dec 2.
- SSRN. 2025 Jul 30.
- Patent. US20250235403A1.
- SSRN. 2025 Jun 24.
- Patent. US20240417738A1.
- Preprints. 2024 Aug 27.
- Research Square Preprint. 2023 Nov 17.
- Research Square Print. 2023 Feb 1.
- Oxid Med Cell Longev. 2022 Oct 12:2022:6264474. [Abstract]
- Research Square Preprint. 2021 Oct.
Customer Validation & Images
-
Histological Imaging/Staining
-
Bio/Physico-chemical Assay
-
Bio/Physico-chemical Assay
-
Bio/Physico-chemical Assay
-
Histological Imaging/Staining
生物活性
製品説明
体内実験
Administration: 3.125 mg/day • skin • 6 days
(1) Prepare BM of lipids
STA and OA were melted at 75 °C followed by the addition of IMQ (3.5% of the BM, w/w) under continuous stirring.
Polysorbate 80 and stearoyl polyoxyl-32 glycerides at a 50:50 ratio were dispersed in water heated separately to 75 °C and added to the BM phase under continuous stirring.
(2) Prepare nanostructured lipid carriers (NLCs)
The mixture was then subjected to high-shear homogenization followed by ultrasonication.
The mixture was then rapidly cooled in an ice bath to allow the formation of NLCs.
Resulted in hyperproliferative keratinocytes and a disturbed epidermal differentiation (parakeratosis).
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
化学情報
-
CAS 番号 2995277-02-4
-
分子量 313.23
-
分子式 C14H18Cl2N4
-
SMILES
NC1=NC2=C(C3=C1N=CN3CC(C)C)C=CC=C2.Cl.Cl
-
別名
R 837 dihydrochloride
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (52)
-
Journal Impact Factor
-
Most Recent
-
Nature
2025 May;641(8061):202-210. PMID: 40140567 -
Nat Commun
NFATc1 supports imiquimod-induced skin inflammation by suppressing IL-10 synthesis in B cells. [Abstract]2016 May 25:7:11724. PMID: 27222343
Imiquimod dihydrochloride purchased from MedChemExpress. Usage Cited in: Nat Commun. 2016 May 25:7:11724. [Abstract]
Freshly prepared splenic B cells are left unstimulated (lanes 1 and 4), or stimulated by 10 μg/mL αIgM for 6 or 24 h (lanes 2 and 3), or by 1 μg/mL IMQ for 6, 24, 48 and 72 h (lanes 5-8), or by αIgM and IMQ for 24 or 48 h (lanes 9+10), respectively.
-
J Nanobiotechnology
Enhancement of antitumor immunotherapy using mitochondria-targeted cancer cell membrane-biomimetic MOF-mediated sonodynamic therapy and checkpoint blockade immunotherapy. [Abstract]2022 May 14;20(1):228. PMID: 35568916
Imiquimod dihydrochloride purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2022 May 14;20(1):228. [Abstract]
TEM image and magnified TEM Image of Zr-TCPP(TPP)/R837@M nanoparticles, scale bar: 200 nm.
Imiquimod dihydrochloride purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2022 May 14;20(1):228. [Abstract]
XPS spectra of Zr-TCPP(TPP)/R837@M.
-
Nucleic Acids Res
COVID19 Drug Repository: text-mining the literature in search of putative COVID19 therapeutics. [Abstract]2021 Jan 8;49(D1):D1113-D1121. PMID: 33166390 -
Theranostics
2023 Apr 9;13(7):2226-2240. PMID: 37153743
Imiquimod dihydrochloride purchased from MedChemExpress. Usage Cited in: Theranostics. 2023 Apr 9;13(7):2226-2240. [Abstract]
Representative images of lung of mice after indicated treatment. PFI: ICG-loaded PF127 hydrogel, PFIR: ropivacaine-loaded PFI hydrogel, PFIM: imiquimod-loaded PFI hydrogel, PFIRM: imiquimod (3 mg) and ropivacaine co-loaded PFI hydrogel.
Imiquimod dihydrochloride purchased from MedChemExpress. Usage Cited in: Theranostics. 2023 Apr 9;13(7):2226-2240. [Abstract]
1. Cumulative release profile of ICG and Imiquimod (3 mg) from PFIRM with or without laser irradiation at 1.2 W/cm2 for 5 min. The absorbance of IMQ and ICG were measured at 320 and 800 nm, respectively, using a Micro UV-Vis Spectrophotometer (LIFEREAL, FC-1100). The assay was repeated three times.
-
-
Acta Pharm Sin B
Macrophage P2Y6R activation aggravates psoriatic inflammation through IL-27-mediated Th1 responses. [Abstract]2024 Oct;14(10):4360-4377. PMID: 39525587 -
Adv Sci (Weinh)
Boron Neutron Capture Therapy-Derived Extracellular Vesicles via DNA Accumulation Boost Antitumor Dendritic Cell Vaccine Efficacy. [Abstract]2024 Sep;11(35):e2405158. PMID: 39021327 -
MedComm (2020)
Tyrosine phosphatase SHP2 exacerbates psoriasis-like skin inflammation in mice via ERK5-dependent NETosis. [Abstract]2022 Mar 4;3(1):e120. PMID: 35281792
Imiquimod dihydrochloride purchased from MedChemExpress. Usage Cited in: MedComm (2020). 2022 Mar 4;3(1):e120. [Abstract]
H&E staining of back skin sections of sham‐ or IMQ‐treated SHP2N KO and WT mice, scale bar = 200 μm.
Imiquimod dihydrochloride purchased from MedChemExpress. Usage Cited in: MedComm (2020). 2022 Mar 4;3(1):e120. [Abstract]
IMQ (10 μM, 2 h) treatment significantly increased the proportion of neutrophils in immune cells, while SHP099 treatment significantly decreased it.
Imiquimod dihydrochloride purchased from MedChemExpress. Usage Cited in: MedComm (2020). 2022 Mar 4;3(1):e120. [Abstract]
Results showed that neutrophil infiltration occurred in the skin tissues after IMQ (10 μM, 2 h) treatment, and SHP099 significantly reversed this phenomenon.
-
Biomaterials
2022 Mar:282:121411. PMID: 35189461 -
Biomaterials
Physiologically triggered injectable red blood cell-based gel for tumor photoablation and enhanced cancer immunotherapy. [Abstract]2021 Apr:271:120724. PMID: 33636549 -
Mol Biomed
ML345 is a potent and selective NLRP3 inflammasome inhibitor with anti-inflammatory activity. [Abstract]2025 Nov 13;6(1):108. PMID: 41231359 -
J Control Release
Liposomal co-delivery of toll-like receptors 3 and 7 agonists induce a hot triple-negative breast cancer immune environment. [Abstract]2023 Sep:361:443-454. PMID: 37558053 -
Cell Death Dis
S1PR3-driven positive feedback loop sustains STAT3 activation and keratinocyte hyperproliferation in psoriasis. [Abstract]2025 Jan 20;16(1):31. PMID: 39833165 -
-
Cell Commun Signal
Identification of a covalent NEK7 inhibitor to alleviate NLRP3 inflammasome-driven metainflammation. [Abstract]2024 Nov 25;22(1):565. PMID: 39587676 -
Cell Commun Signal
TLR7 activation by miR-21 promotes renal fibrosis by activating the pro-inflammatory signaling pathway in tubule epithelial cells. [Abstract]2023 Aug 18;21(1):215. PMID: 37596656 -
Drug Deliv
Biomimetic virus-like mesoporous silica nanoparticles improved cellular internalization for co-delivery of antigen and agonist to enhance Tumor immunotherapy. [Abstract]2023 Dec;30(1):2183814. PMID: 36843529 -
-
Cell Rep
MyD88 in myofibroblasts enhances colitis-associated tumorigenesis via promoting macrophage M2 polarization. [Abstract]2021 Feb 2;34(5):108724. PMID: 33535045
Imiquimod dihydrochloride purchased from MedChemExpress. Usage Cited in: Cell Rep. 2021 Feb 2;34(5):108724. [Abstract]
Primary intestinal NFs were exposed to TLR agonists and IL-1 for 12 h, and OPN mRNA was measured using qPCR analysis. The results were normalized to β-actin. ∗p < 0.05. TLR agonists were used at the following concentrations: TLR1/2 agonist (Pam3CSK4), 100 ng/mL; TLR4 agonist (LPS), 1 μg/mL; TLR7 agonist (Imiquimod; HY-B0180), 100 ng/mL; TLR8 agonist (Motolimod; HY-13773), 250 ng/mL; and IL-1, 5 ng/ml.
-
J Invest Dermatol
Adipocyte-Derived CTRP3 Exhibits Anti-Inflammatory Effects via LAMP1-STAT3 Axis in Psoriasis. [Abstract]2022 May;142(5):1349-1359.e8. PMID: 34687744 -
Pharmaceutics
Functional pH-Responsive Nanoparticles for Immune Reprogramming in MSS Colorectal Cancer via ER Stress-Induced Proteostasis Disruption, PD-L1-Targeting miRNA, and TLR7 Activation. [Abstract]2025 Nov 20;17(11):1503. PMID: 41304839 -
J Ethnopharmacol
Melampodium divaricatum (Rich.) DC. extracts exert anti-inflammatory effects via inhibition of the NLRP3 inflammasome. [Abstract]2026 Oct 28:369:121903. PMID: 42202918 -
J Ethnopharmacol
Guarea microcarpa C. DC. extract inhibits NLRP3 inflammasome by suppressing its ATPase activity. [Abstract]2024 Apr 6:323:117711. PMID: 38176663 -
J Agric Food Chem
Yogurt Alleviates Imiquimod-Induced Psoriasis by Activating the Lactate/GPR81 Signaling Axis in Mice. [Abstract]2024 Jan 17;72(2):1055-1066. PMID: 38170675 -
Inflamm Res
2026 Apr 17;75(1):93. PMID: 41998354 -
EMBO Rep
Licochalcone B specifically inhibits the NLRP3 inflammasome by disrupting NEK7-NLRP3 interaction. [Abstract]2022 Feb 3;23(2):e53499. PMID: 34882936 -
Int Immunopharmacol
Casting NETs on Psoriasis: The modulation of inflammatory feedback targeting IL-36/IL-36R axis. [Abstract]2024 Sep 21;142(Pt B):113190. PMID: 39306890 -
ACS Appl Bio Mater
Polydopamine-Based Multifunctional Platform for Combined Photothermal Therapy, Chemotherapy, and Immunotherapy in Malignant Tumor Treatment. [Abstract]2019 Feb 18;2(2):874-883. PMID: 35016291 -
J Periodontal Res
Toll-Like Receptor 7 Promotes Periodontal Inflammation and Alveolar Bone Resorption Through the NF-κB Signaling Pathway. [Abstract]2025 Feb 25. PMID: 40007244 -
Am J Respir Cell Mol Biol
Neuromedin U Induces Pulmonary ILC2 Activation via the NMUR1 Pathway During Acute RSV Infection. [Abstract]2023 Mar;68(3):256-266. PMID: 36227802 -
-
Eur J Pharm Sci
In Vitro Investigation of Tapinarof-Loaded Nanogels in an Imiquimod-induced HaCaT-THP-1 Co-Culture Model. [Abstract]2026 Mar 19:107510. PMID: 41864521 -
Sci Rep
Aiouea padiformis extract exhibits anti-inflammatory effects by inhibiting the ATPase activity of NLRP3. [Abstract]2024 Mar 4;14(1):5237. PMID: 38433281 -
J Cell Mol Med
Anti-inflammatory effect of Trichospira verticillata via suppression of the NLRP3 inflammasome in neutrophilic asthma. [Abstract]2024 Apr;28(8):e18356. PMID: 38668995 -
J Inflamm Res
2025 Mar 20:18:4213-4231. PMID: 40129872 -
FASEB J
Biphasic Regulation of TLR7/MyD88/IRF7-IFN-β Axis by Toxoplasma gondii Facilitates Immune Evasion. [Abstract]2025 Dec 15;39(23):e71278. PMID: 41307494 -
Arch Microbiol
A BCG-boosting subunit vaccine RS2/DMI induces Th1-polarized immunity by targeting RD6 and secretory antigens of Mycobacterium tuberculosis. [Abstract]2025 Oct 6;207(11):290. PMID: 41051521 -
FEBS Lett
2021 Oct;595(19):2447-2462. PMID: 34387860 -
Tuberculosis
Diagnostic value of five Mycobacterium tuberculosis dormant highly expressed antigens in latent infections and immunogenicity assessment of a novel subunit vaccine PB2-DIMQ. [Abstract]2025 Oct 14:155:102698. PMID: 41108940 -
Biochem Biophys Res Commun
Sequential administration of delta-tocotrienol ameliorates radiation-induced myelosuppression in mice and non-human primates through inducing G-CSF production. [Abstract]2024 Apr 16:704:149661. PMID: 38417343 -
Ir J Med Sci
TLR7 modulates glioblastoma progression through PI3K/AKT/mTOR pathway and immune microenvironment remodeling. [Abstract]2025 Dec 13. PMID: 41389249 -
-
-
-
-
-
-
-
-
Oxid Med Cell Longev
miR-124-3p Delivered Using Exosomes Attenuates the Keratinocyte Response to IL-17A Stimulation in Psoriasis. [Abstract]2022 Oct 12:2022:6264474. PMID: 36275890 -
プロトコル
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
純度とドキュメンテーション
参考文献
[1]. Athina Angelopoulou, et al. Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19. Environ Res. 2020 Sep; 188: 109858. [Content Brief]
[2]. Aditya K Gupta, et al. Imiquimod: a review. J Cutan Med Surg. Nov-Dec 2002;6(6):554-60. [Content Brief]
[3]. Yuji Kan, et al. Imiquimod suppresses propagation of herpes simplex virus 1 by upregulation of cystatin A via the adenosine receptor A1 pathway. J Virol. 2012 Oct;86(19):10338-46. [Content Brief]
[4]. Michael P Schön, et al. The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion. J Invest Dermatol. 2006 Jun;126(6):1338-47. [Content Brief]
[5]. Leslie van der Fits, et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol. 2009, 182, 9. [Content Brief]
[6]. Ajla Smajlović, et al. Molecular and histopathological profiling of imiquimod induced dermatosis in Swiss Wistar rats: contribution to the rat model for novel anti-psoriasis treatments. Mol Biol Rep. 2021, 48, 5. [Content Brief]
[7]. Sangseo Kim, et al. Development and Optimization of Imiquimod-Loaded Nanostructured Lipid Carriers Using a Hybrid Design of Experiments Approach. Int J Nanomedicine. 2023. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Imiquimod dihydrochloride 関連分類
HY-B0180C 関連分類
Powered by Bioz
Keywords